About Semaglutide Canada

Semaglutide Canada is run by a small team of independent researchers and writers who cover GLP-1 medications — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and related treatments — from a Canadian patient perspective.

We compare provider pricing, summarize Health Canada and provincial-formulary information, track the upcoming arrival of generic semaglutide, and review the Canadian telehealth platforms that prescribe GLP-1 medications. Everything we publish is cited and reviewed for accuracy by our editorial team.

We are not a medical practice and we do not provide medical advice. Nothing on this site replaces a consultation with a licensed Canadian physician, nurse practitioner, or pharmacist. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.

How we work

Our articles cite primary sources wherever possible: Health Canada product monographs, peer-reviewed clinical trials, provincial drug formularies, and manufacturer pricing data. We update pages as new information becomes available and show when each page was last updated. How articles are drafted, checked and reviewed is set out in our editorial policy.

Editorial independence

We are reader-supported. When we link to a Canadian telehealth provider, we may receive a referral fee at no extra cost to you. These relationships never determine what we cover or how we rank providers. The six criteria we score providers against are published on our methodology page: cost to start, 12-month total, provincial coverage, clinical oversight, fulfilment and transparency.

Contact

Have a correction, source, or question? Email us at support@semaglutidecanada.com .